Bevacizumab targeted therapy: Validation of angiogenesis as a key target for advanced colorectal cancer

Edward Chu

doi:10.3816/CCC.2004.n.006

Bevacizumab targeted therapy: Validation of angiogenesis as a key target for advanced colorectal cancer

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	16
Number of pages	1
Journal	Clinical colorectal cancer
Volume	4
Issue number	1
DOIs	https://doi.org/10.3816/CCC.2004.n.006
State	Published - May 2004
Externally published	Yes

ASJC Scopus subject areas

Oncology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3816/CCC.2004.n.006

Cite this

@article{d7f028529e944ba4833ea3d675c63c89,

title = "Bevacizumab targeted therapy: Validation of angiogenesis as a key target for advanced colorectal cancer",

author = "Edward Chu",

year = "2004",

month = may,

doi = "10.3816/CCC.2004.n.006",

language = "English (US)",

volume = "4",

pages = "16",

journal = "Clinical colorectal cancer",

issn = "1533-0028",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Bevacizumab targeted therapy

T2 - Validation of angiogenesis as a key target for advanced colorectal cancer

AU - Chu, Edward

PY - 2004/5

Y1 - 2004/5

UR - http://www.scopus.com/inward/record.url?scp=3042569689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042569689&partnerID=8YFLogxK

U2 - 10.3816/CCC.2004.n.006

DO - 10.3816/CCC.2004.n.006

M3 - Editorial

C2 - 15207014

AN - SCOPUS:3042569689

SN - 1533-0028

VL - 4

SP - 16

JO - Clinical colorectal cancer

JF - Clinical colorectal cancer

IS - 1

ER -

Bevacizumab targeted therapy: Validation of angiogenesis as a key target for advanced colorectal cancer

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this